MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.150
+0.020 (1.77%)
Oct 23, 2026, 4:00 PM EDT - Market closed
MAIA Biotechnology Employees
MAIA Biotechnology had 13 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes MAIA Biotechnology the 39,701st largest employer in the world and 5,856th in the United States.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,065,015
Market Cap
69.95M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 13 | 0 | - |
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | -5 | -27.78% |
| Dec 31, 2022 | 18 | 9 | 100.00% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 214 |
| Acrivon Therapeutics | 76 |
| Neumora Therapeutics | 63 |
| Cardiff Oncology | 31 |
| Cognition Therapeutics | 14 |
| Cingulate | 14 |
| Nutriband | 13 |
| ProMIS Neurosciences | 11 |
MAIA News
- 17 days ago - MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer - GlobeNewsWire
- 23 days ago - Diamond Equity releases update note on MAIA Biotechnology - TheFly
- 23 days ago - Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - GlobeNewsWire
- 4 weeks ago - MAIA Biotechnology files to sell 751,879 shares of common stock for holders - TheFly
- 4 weeks ago - MAIA Biotechnology Registration statement: Registration filing - Filings
- 4 weeks ago - MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal - GlobeNewsWire
- 4 weeks ago - MAIA Biotechnology reports Phase 3 trial progress in advanced NSCLC - TheFly
- 4 weeks ago - MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer - GlobeNewsWire